The field of biotechnology is constantly evolving, driven by innovative companies at the forefront of scientific advancements. Union City biotech companies have emerged as key players in this transformation. Union City, CA, has developed into a dynamic hub for biotech innovation, leveraging its strategic location in the San Francisco Bay Area, proximity to academic research centers, and access to top-tier talent. With the global biotech market projected to reach over $2.44 trillion by 2028, Union City’s biotech ecosystem is playing a pivotal role in shaping the future of healthcare and scientific research. In this article, we explore five exceptional companies making waves in 2025. From pioneering protein expression technology to cutting-edge biomanufacturing and regenerative medicine, these organizations are transforming lives and advancing the industry.
Celltheon: Revolutionizing Protein Expression Technology
Celltheon continues to lead the way in protein expression technology, offering cutting-edge solutions for efficient protein production. Their proprietary OmniCHO™ platform accelerates drug discovery and development processes, enabling the creation of novel therapeutics. This platform is recognized for its high yield and scalability, making it a preferred choice for biopharma companies looking to streamline biologics production.
This year, Celltheon expanded its partnerships with top-tier biopharma companies and academic institutions, further strengthening its position in the market. The company has also been investing in advanced AI-driven modeling tools to optimize cell line development, significantly reducing time-to-market for new biologics. With demand for biologics growing globally, Celltheon’s innovations are poised to make a significant impact on therapeutic availability and affordability, cementing its role as a leader among Union City biotech companies.
FibrAlign: Advancing Biomaterials with Collagen-Based Matrices
FibrAlign specializes in collagen-based matrices that accurately mimic various tissue patterns. Their flagship product, BioBridge® Collagen Matrix, has gained widespread recognition for applications in tissue engineering and regenerative medicine. In 2025, FibrAlign’s focus on secondary lymphedema treatment has opened new avenues for addressing unmet medical needs.
FibrAlign is also collaborating with research institutions to explore the potential of their biomaterials in chronic wound healing and vascular grafts. With advancements in 3D bioprinting, FibrAlign has developed methods to customize collagen scaffolds, offering tailored solutions for various clinical applications. This versatility has positioned them as a leader in biomaterial innovation. Their products are also being explored for advanced drug delivery systems, making them a standout among Union City biotech companies.
Mizuho OSI: Enhancing Surgical Procedures with State-of-the-Art Tables
Mizuho OSI remains a trusted provider of surgical and hospital tables, specializing in solutions for spinal and orthopedic procedures. Their ergonomic designs prioritize patient comfort and support medical professionals. In 2025, Mizuho OSI introduced next-generation tables with integrated digital tracking systems, further enhancing surgical outcomes.
These smart tables are equipped with IoT capabilities, allowing real-time monitoring of patient positioning and pressure distribution. This innovation has been particularly beneficial in reducing surgical complications and improving workflow efficiency in operating rooms. Mizuho OSI has also expanded its product line to include robotic-assisted surgery platforms, further cementing its role in advancing surgical technologies. Their commitment to innovation ensures better outcomes for patients undergoing complex procedures, solidifying their reputation in Union City biotech companies.
Gyre Therapeutics: Innovating Precision Medicine
Gyre Therapeutics, a trailblazer in precision medicine, develops protease therapeutics for hematological and inflammatory diseases. Headquartered in Union City, Gyre Therapeutics' strategic advancements in protease-based treatments are addressing rare bleeding disorders with high efficacy and safety. Their lead candidate, a next-generation Factor IX variant, has shown promising results in clinical trials for hemophilia B.
In addition to their work in hematology, Gyre Therapeutics is exploring protease inhibitors for inflammatory diseases, aiming to offer targeted and personalized therapeutic options. The company’s commitment to precision medicine is exemplified by its partnerships with genomic research firms to identify biomarkers for better patient stratification. Gyre Therapeutics' groundbreaking research continues to attract global attention and investment, reaffirming its prominence among Union City biotech companies.
Sepragen: Enabling Efficient Bioprocessing with Chromatography and Bioreactors
Sepragen continues to focus on bioprocessing tools such as chromatography systems and bioreactors, essential for biopharmaceutical manufacturing. Their advanced technologies streamline separation and purification processes, ensuring the production of high-quality biopharmaceuticals.
This year, Sepragen has made strides in improving downstream processing efficiency for gene therapy products. Their proprietary Quick-Scale™ chromatography system has been widely adopted for its ability to handle large-scale purification while maintaining high resolution and recovery rates. Additionally, Sepragen has introduced modular bioreactor systems, enabling customizable solutions for various biomanufacturing needs, from monoclonal antibodies to viral vectors. These developments underscore Sepragen’s commitment to driving efficiency and quality in biomanufacturing, making it a key player among Union City biotech companies.
Revolutionize Your R&D with Scispot
To stay ahead in this rapidly evolving landscape, biotech companies must embrace the power of technology. That’s where Scispot comes in. With our TechBio toolkit, you can streamline your research processes, automate tasks, integrate data, and scale your operations effectively.
Scispot’s solutions are tailored to modern biotech challenges, enabling companies to build their digital backbone. From automating workflows to creating personalized dashboards powered by AI, Scispot ensures your R&D stays agile and efficient. Our platform integrates seamlessly with existing systems, offering tools for data harmonization, compliance reporting, and real-time analytics—all critical for scaling biotech operations.
Join the growing community of Union City biotech companies and other innovators transforming their research with Scispot. Together, let’s redefine the possibilities in biotech R&D.
Conclusion
The field of biotechnology is thriving with innovation, and these top 5 companies in Union City, CA, are at the forefront of this exciting industry in 2025. From groundbreaking therapeutics to advanced biomaterials and game-changing research tools, these companies are driving advancements that have the potential to transform healthcare and improve lives. Union City’s unique ecosystem of collaboration, innovation, and cutting-edge facilities has made it a hub for biotech excellence. With continuous advancements in precision medicine, regenerative therapies, and bioprocessing technologies, these companies are setting benchmarks for the global biotech landscape.
As the demand for biotech solutions continues to rise, Union City biotech companies stand out as a beacon of progress, ensuring that innovation and access go hand-in-hand to create a healthier future for all.
